147 related articles for article (PubMed ID: 32634780)
1. Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.
Douglas MP; Gray SW; Phillips KA
J Natl Compr Canc Netw; 2020 Jul; 18(7):866-872. PubMed ID: 32634780
[TBL] [Abstract][Full Text] [Related]
2. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.
Douglas MP; Ragavan MV; Chen C; Kumar A; Gray SW; Blakely CM; Phillips KA
J Natl Compr Canc Netw; 2023 Jun; 21(6):609-616.e4. PubMed ID: 37308126
[TBL] [Abstract][Full Text] [Related]
3. Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans.
Li Y; Heer AK; Sloane HS; Edelstein DL; Tie J; Gibbs P; Barzi A
JAMA Health Forum; 2024 May; 5(5):e241270. PubMed ID: 38819797
[TBL] [Abstract][Full Text] [Related]
4. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling.
Wang G; Beattie MS; Ponce NA; Phillips KA
Genet Med; 2011 Dec; 13(12):1045-50. PubMed ID: 21844812
[TBL] [Abstract][Full Text] [Related]
5. Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer.
Lu CY; Loomer S; Ceccarelli R; Mazor KM; Sabin J; Clayton EW; Ginsburg GS; Wu AC
J Pers Med; 2018 May; 8(2):. PubMed ID: 29772692
[TBL] [Abstract][Full Text] [Related]
6. Value-based interventional pain management: a review of medicare national and local coverage determination policies.
Manchikanti L; Falco FJ; Benyamin RM; Helm S; Singh V; Hirsch JA
Pain Physician; 2013; 16(3):E145-80. PubMed ID: 23703416
[TBL] [Abstract][Full Text] [Related]
7. Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs.
Chambers JD; Wilkinson CL; Anderson JE; Chenoweth MD
J Manag Care Spec Pharm; 2016 Oct; 22(10):1176-81. PubMed ID: 27668566
[TBL] [Abstract][Full Text] [Related]
8. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.
Trosman JR; Douglas MP; Liang SY; Weldon CB; Kurian AW; Kelley RK; Phillips KA
Value Health; 2020 May; 23(5):551-558. PubMed ID: 32389219
[TBL] [Abstract][Full Text] [Related]
9. Private payers disagree with Medicare over medical device coverage about half the time.
Chambers JD; Chenoweth M; Thorat T; Neumann PJ
Health Aff (Millwood); 2015 Aug; 34(8):1376-82. PubMed ID: 26240252
[TBL] [Abstract][Full Text] [Related]
10. Private payer coverage policies for ApoE-e4 genetic testing.
Arias JJ; Tyler AM; Douglas MP; Phillips KA
Genet Med; 2021 Apr; 23(4):614-620. PubMed ID: 33420342
[TBL] [Abstract][Full Text] [Related]
11. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.
Chambers JD; Saret CJ; Anderson JE; Deverka PA; Douglas MP; Phillips KA
Int J Technol Assess Health Care; 2017 Jan; 33(4):534-540. PubMed ID: 29065945
[TBL] [Abstract][Full Text] [Related]
12. Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited.
Douglas MP; Parker SL; Trosman JR; Slavotinek AM; Phillips KA
Genet Med; 2019 Jan; 21(1):152-160. PubMed ID: 29997388
[TBL] [Abstract][Full Text] [Related]
13. Genetic testing insurance coverage trends: a review of publicly available policies from the largest US payers.
Graf MD; Needham DF; Teed N; Brown T
Per Med; 2013 May; 10(3):235-243. PubMed ID: 29768740
[TBL] [Abstract][Full Text] [Related]
14. How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab.
Dusetzina SB; Ellis S; Freedman RA; Conti RM; Winn AN; Chambers JD; Alexander GC; Huskamp HA; Keating NL
J Oncol Pract; 2015 Jul; 11(4):313-8. PubMed ID: 26060224
[TBL] [Abstract][Full Text] [Related]
15. Alignment of health plan coverage policies for somatic multigene panel testing with clinical guidelines in select solid tumors.
Wong WB; Anina D; Lin CW; Adams DV
Per Med; 2022 May; 19(3):171-180. PubMed ID: 35118882
[TBL] [Abstract][Full Text] [Related]
16. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?
Phillips KA
JAMA; 2018 Jun; 319(23):2379-2380. PubMed ID: 29710095
[No Abstract] [Full Text] [Related]
17. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.
Trosman JR; Van Bebber SL; Phillips KA
J Oncol Pract; 2010 Sep; 6(5):238-42. PubMed ID: 21197187
[TBL] [Abstract][Full Text] [Related]
18. The interface of Medicare coverage decision-making and emerging molecular-based laboratory testing.
Burken MI; Wilson KS; Heller K; Pratt VM; Schoonmaker MM; Seifter E
Genet Med; 2009 Apr; 11(4):225-31. PubMed ID: 19282775
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
20. Mapping US commercial payers' coverage policies for medical interventions.
Chambers JD; Chenoweth MD; Neumann PJ
Am J Manag Care; 2016 Sep; 22(9):e323-8. PubMed ID: 27662396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
